Insight
The transitional mechanism for the alternative extrapolation
Implications of the European Commission’s proposal for the Solvency II Directive.
Pharmacy benefit managers offer a wide range of clinical programs designed to improve health outcomes for members, while reducing overall healthcare costs. Plan sponsors may find it challenging to develop a process that effectively evaluates these programs. This paper explores industry best practices plan sponsors can use to consistently assess the value of both new and existing clinical programs.
Insight
Implications of the European Commission’s proposal for the Solvency II Directive.